Expression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosis

Maruta,Sugure; Miyata,Yasuyoshi; Sagara,Yuji; Kanda,Shigeru; Iwata,Takahisa; Watanabe,Shin-ichi; Sakai,Hideki; Hayashi,Tomayoshi; Kanetake,Hiroshi

doi:10.3892/ol_00000073

Expression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosis

Authors:
- Sugure Maruta
- Yasuyoshi Miyata
- Yuji Sagara
- Shigeru Kanda
- Takahisa Iwata
- Shin-ichi Watanabe
- Hideki Sakai
- Tomayoshi Hayashi
- Hiroshi Kanetake
View Affiliations

Affiliations: Department of Urology, Nagasaki University Graduate School of Biomedical Science, Nagasaki 852-8501, Japan
Published online on: May 1, 2010 https://doi.org/10.3892/ol_00000073
Pages: 417-421

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) are associated with cell invasion under various physiological and pathological conditions. Among MMPs, MMP-10 is reported to correlate with a high pT stage and progression in a variety of cancer types. However, the clinical and pathological significance of MMP-10 in human prostate cancer tissues remains unclear. This study aimed to clarify the role of MMP-10 in non-metastatic prostate cancer. Sixty-three specimens were obtained by radical prostatectomy. MMP-10 expression, Ki-67, CD34 and apoptotic cells were examined using an immunohistochemical technique and the terminal deoxynucleotidyl transferase-mediated nick end-labeling method. The proliferation index (PI), apoptotic index (AI), microvessel density (MVD) and cell renewal index (CRI=PI/AI) were calculated. The relationship between MMP-10 expression and clinicopathological features, as well as PI, AI, MVD and CRI were investigated. MMP-10 was mainly detected in cancer cell cytoplasm, and the proportion of MMP-10-expressing cancer cells (median 13.8%) was significantly higher (P<0.001) than non-tumoral gland cells (2.4%). Similarly, the proportion of MMP-10-expressing cancer cells was significantly higher (P=0.007) in stage pT3 (median 22.3%) than in pT2 (11.3%) tumors and was correlated with blood vessel invasion (P=0.025). In addition, its expression level correlated significantly with CRI (r=0.34, P=0.001), but not with PI, AI or MVD. Multivariate analysis identified MMP-10 expression to be closely associated with pT stage (OR 3.76, 95% CI 1.14-12.34, P=0.029). Our results suggest that the overexpression of MMP-10 produces an imbalance in cancer cell proliferation and apoptosis, thereby contributing to cancer cell progression of non-metastatic prostate cancer.

View Figures

View References

1	Matsushima H, Goto T, Hosaka Y, Kitamura T and Kawabe K: Correlation between proliferation, apoptosis and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer. 85:1822–1827. 1998. View Article : Google Scholar : PubMed/NCBI
2	Visakorpi T, Kallioniemi O-P, Koivula T and Isola J: New prognostic factors in prostatic carcinoma. Eur Urol. 24:438–449. 1993.PubMed/NCBI
3	Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:401–409. 1993.PubMed/NCBI
4	Egelbald M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar
5	Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J. 7:2062–2072. 1994.PubMed/NCBI
6	Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Koga S and Kanetake H: Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implication and clinical significance for invasion and metastasis. Clin Cancer Res. 15:6998–7003. 2006. View Article : Google Scholar
7	Wood M, Fudge K, Mohler AR, Frost AR, Garcia F, Wang M and Stearns ME: In situ hybridization studies of metalloproteinase 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis. 15:246–258. 1997. View Article : Google Scholar : PubMed/NCBI
8	Pavlaki M and Zucker S: Matrix metalloproteinase inhibitors (MMPIs): the beginning of the phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22:177–203. 2003. View Article : Google Scholar : PubMed/NCBI
9	Arlt M, Kopitz C, Pennington KL, Watson KL, Krell HW, Bode W, Gansbacher B, Khokha R, Edward DR and Krüger A: Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlated with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. 62:5543–5550. 2002.PubMed/NCBI
10	Miyazaki K, Koshikawa N, Hasegawa S, Momiyama N, Nagashima Y, Moriyama K, Ichikawa Y, Ishikawa T, Mitsuhashi M and Shimada H: Matrilysin as target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. Cancer Chemother Pharmacol. 43:S52–S55. 1999. View Article : Google Scholar : PubMed/NCBI
11	Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK and Ralhan R: Stromelysis-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev. 26:222–228. 2002. View Article : Google Scholar : PubMed/NCBI
12	Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M and Kanetake H: Expression of matrix metalloproteinase-10 in renal cell carcinoma. Eur Urol. 52:791–797. 2007. View Article : Google Scholar : PubMed/NCBI
13	Meyer E, Vollmer J-Y, Bovey R and Stamenkovic I: Matrix metalloproteinase 9 and 10 inhibit protein kinase C-potentiated, p-53-mediated apoptosis. Cancer Res. 65:4261–4272. 2005. View Article : Google Scholar : PubMed/NCBI
14	Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T and Kanetake H: Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2 and survival. Clin Cancer Res. 9:1741–1749. 2003.
15	Bai M, Agnantis N, Kamina S, Demou A, Zagorianakou P, Katsaraki A and Kanavaros P: In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res. 3:276–283. 2001. View Article : Google Scholar : PubMed/NCBI
16	Singh S, Singh UP, Grizzle WE and Lillard JW Jr: CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 84:1666–1676. 2004. View Article : Google Scholar : PubMed/NCBI
17	Singh S, Singh UP, Stiles JK and Lillard JW Jr: Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 10:8743–8750. 2004. View Article : Google Scholar : PubMed/NCBI
18	Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T and Imai K: Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer. 95:290–294. 2001. View Article : Google Scholar : PubMed/NCBI
19	Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y and Chen KY: Matrix metalloproteinase expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 100:1835–1843. 2005. View Article : Google Scholar : PubMed/NCBI
20	Navarrete MA, Maier CM, Falzoni R, Gerk de Azevedo Quadros L, Kima GR, Baracat EC and Nazário AC: Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res. 7:R306–R313. 2005. View Article : Google Scholar